Antonio Gil‐Gómez

821 total citations
35 papers, 539 citations indexed

About

Antonio Gil‐Gómez is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Antonio Gil‐Gómez has authored 35 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Epidemiology, 12 papers in Hepatology and 9 papers in Molecular Biology. Recurrent topics in Antonio Gil‐Gómez's work include Liver Disease Diagnosis and Treatment (23 papers), Liver Disease and Transplantation (8 papers) and MicroRNA in disease regulation (4 papers). Antonio Gil‐Gómez is often cited by papers focused on Liver Disease Diagnosis and Treatment (23 papers), Liver Disease and Transplantation (8 papers) and MicroRNA in disease regulation (4 papers). Antonio Gil‐Gómez collaborates with scholars based in Spain, United States and Italy. Antonio Gil‐Gómez's co-authors include Manuel Romero‐Gómez, Ángela Rojas, Javier Ampuero, Rocío Gallego‐Durán, Rocío Múñoz‐Hernández, Rocío Montero‐Vallejo, M. García‐Valdecasas, J.A. Del Campo, Juan Bautista and Isidora Ranchal and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Stroke.

In The Last Decade

Antonio Gil‐Gómez

34 papers receiving 529 citations

Peers

Antonio Gil‐Gómez
Antonio Gil‐Gómez
Citations per year, relative to Antonio Gil‐Gómez Antonio Gil‐Gómez (= 1×) peers Ángela Rojas

Countries citing papers authored by Antonio Gil‐Gómez

Since Specialization
Citations

This map shows the geographic impact of Antonio Gil‐Gómez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Gil‐Gómez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Gil‐Gómez more than expected).

Fields of papers citing papers by Antonio Gil‐Gómez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Gil‐Gómez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Gil‐Gómez. The network helps show where Antonio Gil‐Gómez may publish in the future.

Co-authorship network of co-authors of Antonio Gil‐Gómez

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Gil‐Gómez. A scholar is included among the top collaborators of Antonio Gil‐Gómez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Gil‐Gómez. Antonio Gil‐Gómez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Díaz, Luis Antonio, Antonio Gil‐Gómez, Jeremy P. Burton, et al.. (2024). Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 31(Suppl). S94–S111. 26 indexed citations
2.
Múñoz‐Hernández, Rocío, Antonio Gil‐Gómez, R. Aller, et al.. (2023). Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD. Liver International. 43(9). 1909–1919. 5 indexed citations
3.
Silvestri, Alessandra, Antonio Gil‐Gómez, Daniele Braga, et al.. (2023). Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and expanding A. muciniphila. Cell Reports Medicine. 4(10). 101235–101235. 16 indexed citations
4.
Rojas, Ángela, et al.. (2022). Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. Journal of Clinical and Translational Hepatology. 10(2). 356–362. 16 indexed citations
5.
Ampuero, Javier, Rocío Gallego‐Durán, Douglas Maya‐Miles, et al.. (2022). Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. Journal of Gastroenterology. 57(5). 357–371. 8 indexed citations
6.
Múñoz‐Hernández, Rocío, Ángela Rojas, Antonio Gil‐Gómez, et al.. (2022). Extracellular Vesicles as Biomarkers in Liver Disease. International Journal of Molecular Sciences. 23(24). 16217–16217. 18 indexed citations
7.
Gil‐Gómez, Antonio, Paola Brescia, María Rescigno, & Manuel Romero‐Gómez. (2021). Gut–Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Seminars in Liver Disease. 41(2). 191–205. 14 indexed citations
8.
Gil‐Gómez, Antonio, Ángela Rojas, Changhai Liu, et al.. (2021). Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World Journal of Gastroenterology. 27(48). 8343–8356. 5 indexed citations
9.
Múñoz‐Hernández, Rocío, Rocío Gallego‐Durán, Rocío Montero‐Vallejo, et al.. (2021). Circulating PCSK9 levels are correlated with advanced disease in patients with biopsy-proven non-alcoholic fatty liver disease.. Atherosclerosis. 331. e142–e143. 1 indexed citations
10.
Zhang, Wenting, Antonio Gil‐Gómez, Changhai Liu, Shuaishuai Gao, & Manuel Romero‐Gómez. (2021). Diagnostic accuracy of circulating microRNA in hepatitis B virus-related hepatocellular carcinoma: a meta-analysis based on Asian data. Revista Española de Enfermedades Digestivas. 114(5). 280–288. 2 indexed citations
11.
Gallego‐Durán, Rocío, Antonio Gil‐Gómez, Ángela Rojas, et al.. (2019). Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. Revista Española de Enfermedades Digestivas. 111(4). 301–307. 3 indexed citations
12.
Ampuero, Javier, Antonio Gil‐Gómez, María del Mar Viloria, et al.. (2019). Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. Liver International. 40(4). 921–930. 11 indexed citations
13.
Rojas, Ángela, Paloma Gallego, Antonio Gil‐Gómez, et al.. (2018). Natural Extracts Abolished Lipid Accumulation in Cells Harbouring non-favourable PNPLA3 genotype. Annals of Hepatology. 17(2). 242–249. 11 indexed citations
14.
Campo, J.A. Del, M. García‐Valdecasas, Antonio Gil‐Gómez, et al.. (2018). Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS ONE. 13(1). e0191805–e0191805. 34 indexed citations
15.
Ampuero, Javier, Antonio Gil‐Gómez, Rocío Montero‐Vallejo, et al.. (2018). miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology. 69(6). 1335–1348. 126 indexed citations
16.
Gil‐Gómez, Antonio, Isidora Ranchal, Ángela Rojas, et al.. (2018). Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. Revista Española de Enfermedades Digestivas. 110(7). 427–433. 7 indexed citations
17.
Rojas, Ángela, et al.. (2018). Performance of different biomarkers for the management of hepatocellular carcinoma. Hepatoma Research. 4(7). 31–31. 7 indexed citations
18.
López-González, Miguel Angel, et al.. (2012). Acute-Phase Inflammatory Response in Idiopathic Sudden Deafness: Pathogenic Implications. SHILAP Revista de lepidopterología. 2012. 1–4. 9 indexed citations
19.
Gil‐Gómez, Antonio, et al.. (2003). Resultados de la Central de Balances en la Comunidad de Madrid 2001 y avance de 2002. Dialnet (Universidad de la Rioja). 21(1). 17–24. 1 indexed citations
20.
Burgess, John, et al.. (1986). Salt effects in reactions between ions of opposite charge. Transition Metal Chemistry. 11(5). 166–169. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026